drugset / Trial / NCT07132684

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

NCT07132684

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is a multicenter, randomized, controlled phase III clinical trial aimed at comparing the efficacy of two induction chemotherapy regimens-VA (Venetoclax + Azacitidine) and D/IA (Daunorubicin/Idarubicin + Cytarabine)-in elderly patients (aged 55-75) with acute myeloid leukemia (AML) who are fit for intensive chemotherapy.

Timeline

Start
2025-08-31
Primary completion
2027-08-30
Completion
2028-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2
Subject Cytarabine Small molecule 100 mg/m2
Comparator Daunorubicin Small molecule 30 mg/m2
Comparator Idarubicin Small molecule 8 mg/m2
Subject Venetoclax Small molecule 400 mg